Waters Co. (WAT) Receives $205.83 Average Target Price from Analysts

Shares of Waters Co. (NYSE:WAT) have earned an average recommendation of “Hold” from the nineteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $205.83.

A number of analysts recently weighed in on the stock. Cleveland Research raised shares of Waters from a “sell” rating to a “neutral” rating in a research note on Thursday, October 11th. Morgan Stanley upped their target price on shares of Waters from $204.00 to $211.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 10th. UBS Group assumed coverage on shares of Waters in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $210.00 target price on the stock. Leerink Swann cut shares of Waters from an “outperform” rating to a “market perform” rating in a research note on Monday, October 8th. Finally, Zacks Investment Research cut shares of Waters from a “hold” rating to a “sell” rating in a research note on Monday, September 24th.

Shares of NYSE:WAT traded up $1.45 on Friday, hitting $189.57. 14,931 shares of the company were exchanged, compared to its average volume of 548,671. Waters has a one year low of $177.25 and a one year high of $220.20. The company has a debt-to-equity ratio of 0.58, a quick ratio of 5.95 and a current ratio of 6.58. The company has a market cap of $15.00 billion, a price-to-earnings ratio of 24.89, a PEG ratio of 2.39 and a beta of 0.93.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, July 24th. The medical instruments supplier reported $1.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.03. Waters had a net margin of 2.12% and a return on equity of 27.85%. The company had revenue of $596.20 million for the quarter, compared to the consensus estimate of $598.73 million. During the same quarter in the previous year, the firm posted $1.76 EPS. The business’s revenue was up 6.8% compared to the same quarter last year. Equities analysts predict that Waters will post 8.11 EPS for the current year.

In other Waters news, SVP Elizabeth B. Rae sold 4,000 shares of the business’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $190.62, for a total value of $762,480.00. Following the transaction, the senior vice president now directly owns 9,443 shares in the company, valued at $1,800,024.66. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.98% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in WAT. Knowledge Leaders Capital LLC raised its stake in shares of Waters by 1.0% during the second quarter. Knowledge Leaders Capital LLC now owns 26,727 shares of the medical instruments supplier’s stock worth $5,174,000 after buying an additional 277 shares during the last quarter. MainStreet Investment Advisors LLC raised its stake in shares of Waters by 6.9% during the second quarter. MainStreet Investment Advisors LLC now owns 4,602 shares of the medical instruments supplier’s stock worth $891,000 after buying an additional 298 shares during the last quarter. Aviva PLC raised its stake in shares of Waters by 0.8% during the second quarter. Aviva PLC now owns 38,965 shares of the medical instruments supplier’s stock worth $7,543,000 after buying an additional 303 shares during the last quarter. Armstrong Henry H Associates Inc. raised its stake in shares of Waters by 2.2% during the second quarter. Armstrong Henry H Associates Inc. now owns 14,319 shares of the medical instruments supplier’s stock worth $2,772,000 after buying an additional 310 shares during the last quarter. Finally, Linscomb & Williams Inc. raised its stake in shares of Waters by 14.2% during the second quarter. Linscomb & Williams Inc. now owns 3,113 shares of the medical instruments supplier’s stock worth $603,000 after buying an additional 386 shares during the last quarter. Hedge funds and other institutional investors own 99.31% of the company’s stock.

Waters Company Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Featured Story: Exchange-Traded Funds (ETFs)

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply